IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC Recall

Ongoing
Drugs
Class II — Moderate

Recall Date

Oct 14, 2026

Company

J&J INNOVATIVE MEDICINE

Source

FDA

Units

49 vials

Reason: Presence of particulate matter.

Class II: Use of the product may cause temporary or medically reversible health problems.

Official FDA recall notice

Information is from official FDA notices. Do not stop taking any medication without consulting your doctor or pharmacist first — the risks of stopping may be greater than the risk from the recalled product.

Recall Details

Description

Presence of particulate matter.

Reason for Recall

Presence of particulate matter.

Product: IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC
Official Recall ID: FDA-DRUG-D-0016-2027
Units affected: 49 vials

What Should I Do?

Check your lot number. Don't stop taking a prescribed medication without talking to your pharmacist or doctor. Contact the pharmacy where you got it about a replacement.

Quantity: 49 vials

Remediation GuideAction Required

5-step guide to help you action required this recalled product. Click Start Remediation to track your progress.

1
Confirm Your Product Is Affected
2
Read the Full Recall Notice
3
Stop Using the Product if in Doubt

+2 more steps…

View Official Recall Notice (FDA)

Last updated October 21, 2026

Injured by a recalled product?

Our legal partners offer free consultations for recall victims.

Get Free Legal Help →Sponsored

Stay Informed

Weekly recall digest — free, no spam.